Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

RecruitingLast updated: 25 September 2025

RESELECT2: A study evaluating whether two drugs are safe to use in people with poor graft function or aplastic anaemia, and whether they can improve blood counts and help patients avoid needing transfusions or other supportive treatmentsREscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2

Trial purpose

Medical clipboardCancer treatment

Tumor type

Blood Cancers Haematological

Age

People18+

Trial acronym

RESELECT2

Clinical summary

Summary

This study is assessing how safe and effective the drugs ruxolitinib and eltrombopag are in people with relapsed or refractory aplastic anaemia or post graft function following allogenic stem cell transplantation (ASCT).

The study will consist of screening and enrolment (up to 28 days), treatment (12 weeks), and follow up (up to 9 months post enrolment). Therefore, the maximum time on study for a single patient will be a maximum of 12 months.

Upon enrolment, participants in the intervention arm will commence treatment with Ruxolitinib and Eltrombopag. Dose adjustments may be required based on lack of efficacy or thrombocytopenia. 

Conditions

This trial is treating people with poor graft function or relapsed or refractor aplastic anaemia

Eligibility

Inclusion

Patient must meet ALL of the following:

  1. Poor Graft function OR Relapsed/refractory AA

    1. Poor Graft Function defined as follows:≥95% donor chimerism at last reading OR ≥95% CD3 negative chimerism; ≥2 Lineage cytopenias defined as:

      Thrombocytopenia:

      • 30x109 /L from D40-D60 OR
      • 50 x10 9/L from D60 onwards; Neutropenia requiring filgrastim support at any time post D40; Hb less than 80g/L;
    2. Relapsed /Refractory AA defined as: Relapse after stem cell transplant OR relapsed post/refractory to 1st line immunosuppression without an unrelated donor identified.
  2. Age ≥18
  3. ECOG performance status 0-1
  4. Life expectancy greater than 6 months
  5. Patient's written informed consent

Exclusion

  1. Active Grade 3-4 acute GVHD
  2. Relapsed or progressive disease on screening bone marrow biopsy or most recent PET imaging.
  3. Active second malignancy currently requiring treatment
  4. Human Immuno-deficiency Virus (HIV) infection.
  5. Any coexisting medical or psychological condition that would preclude participation in the required study procedures.
  6. Female patients who are both lactating and breast-feeding or have a positive serum pregnancy test during the screening period or a positive pregnancy test on Day 1 before first dose of study drug

Inclusion

  • You have the type of cancer, symptoms, or health risks that this clinical trial is focused on.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:

Trial sponsor

Melbourne Health

Scientific Title

REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information